Patents by Inventor Peter Dove

Peter Dove has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
    Patent number: 10696670
    Abstract: A novel class of fluorinated derivatives of Formula I have been prepared and found to be useful in the treatment of cancers and other disorders related mediated by Bromodomain-Containing Proteins.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: June 30, 2020
    Assignee: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter Dove
  • HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS
    Publication number: 20200031825
    Abstract: Compounds of Formula I and II have been prepared for use in the treatment of diseases, disorders or conditions treatable by activation of the stimulator of interferon genes (STING) adaptor protein, such as in the treatment or prevention of cancers.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 30, 2020
    Applicant: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter DOVE, Zezhou WANG, Hoi Ying LIN, David Alexander ROSA, Jeffrey Todd WINSTON
  • FLUORINATED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS INHIBITORS OF BROMODOMAIN CONTAINING PROTEINS
    Publication number: 20190202825
    Abstract: A novel class of fluorinated derivatives of Formula I have been prepared and found to be useful in the treatment of cancers and other disorders related mediated by Bromodomain-Containing Proteins.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 4, 2019
    Applicant: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter Dove
  • Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
    Patent number: 10259809
    Abstract: A novel class of fluorinated derivatives of Formula (I) have been prepared and found to be useful in the treatment of cancers and other disorders related mediated by Bromodomain-Containing Proteins.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: April 16, 2019
    Assignee: TRILLIUM THERAPEUTICS INC.
    Inventors: Abdelmalik Slassi, Peter Dove
  • NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS
    Publication number: 20190016689
    Abstract: A novel class of fluorinated derivatives of Formula (I) have been prepared and found to be useful in the treatment of cancers and other EGFR related disorders.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 17, 2019
    Applicant: TRILLIUM THERAPEUTICS INC.
    Inventors: Abdelmalik Slassi, Peter Dove
  • NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS
    Publication number: 20180050993
    Abstract: A novel class of fluorinated derivatives of Formula I have been prepared and found to be useful in the treatment of cancers and other EGFR related disorders.
    Type: Application
    Filed: February 3, 2016
    Publication date: February 22, 2018
    Applicant: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter Dove
  • FLUORINATED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS INHIBITORS OF BROMODOMAIN CONTAINING PROTEINS
    Publication number: 20180016271
    Abstract: A novel class of fluorinated derivatives of Formula (I) have been prepared and found to be useful in the treatment of cancers and other disorders related mediated by Bromodomain-Containing Proteins.
    Type: Application
    Filed: February 3, 2016
    Publication date: January 18, 2018
    Applicant: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter Dove
  • PROCESS FOR THE SYNTHESIS OF DIFLUOROMETHYL ETHER-BASED COMPOUNDS
    Publication number: 20180016227
    Abstract: The present application relates to a novel process for the preparation of difluoromethyl ether-based derivatives from, for example, aliphatic and aromatic hydroxyl precursors, compositions comprising these compounds and their use, in particular as precursors for medicines for the treatment of diseases, disorders or conditions.
    Type: Application
    Filed: February 3, 2016
    Publication date: January 18, 2018
    Applicant: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter Dove
  • Enhanced communication of electronic reminders
    Patent number: 9762523
    Abstract: A method, computer-readable medium and system for providing automatic or electronic reminders are disclosed. An attribute associated with a task may be used in combination with information about a user to provide an electronic reminder to the user for the task at a relevant or appropriate time to enable the task to be completed. As such, at least one attribute associated with a task and information about a user may be used to automatically determine a time for communicating an electronic reminder to the user.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: September 12, 2017
    Assignee: EGAIN COMMUNICATIONS
    Inventors: Ashutosh Roy, Ian Jones, Peter Dove
  • FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS
    Publication number: 20160347792
    Abstract: The present application relates to novel fluorinated epoxyketone-based compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition.
    Type: Application
    Filed: August 12, 2016
    Publication date: December 1, 2016
    Applicant: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter Dove
  • Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
    Patent number: 9441012
    Abstract: The present application relates to novel fluorinated epoxyketone-based compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition, in particular, the present application includes compounds of Formula I, and compositions and uses thereof.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: September 13, 2016
    Assignee: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter Dove
  • FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS
    Publication number: 20150218212
    Abstract: The present application relates to novel fluorinated epoxyketone-based tetrapeptide compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition.
    Type: Application
    Filed: August 21, 2013
    Publication date: August 6, 2015
    Applicant: FLUORINOV PHARMA INC.
    Inventors: Abdelmalik Slassi, Peter Dove
  • FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS
    Publication number: 20150203534
    Abstract: The present application relates to novel fluorinated epoxyketone-based compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition, in particular, the present application includes compounds of Formula I, and compositions and uses thereof:
    Type: Application
    Filed: August 13, 2013
    Publication date: July 23, 2015
    Applicant: FLUORINOV PHARMA INC.
    Inventors: Abdelmalik Slassi, Peter Dove
  • BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY
    Publication number: 20140163016
    Abstract: The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.
    Type: Application
    Filed: December 11, 2013
    Publication date: June 12, 2014
    Applicant: NeurAxon, Inc.
    Inventors: Jailall RAMNAUTH, Subhash C. Annedi, Sarah Silverman, Peter Dove, Shawn Maddaford, Suman Rakhit
  • Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity
    Patent number: 8618286
    Abstract: The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. Exemplary compounds are of the formula: The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: December 31, 2013
    Assignee: NeurAxon, Inc.
    Inventors: Jailall Ramnauth, Subhash C. Annedi, Sarah Silverman, Peter Dove, Shawn Maddaford, Suman Rakhit
  • BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY
    Publication number: 20120122855
    Abstract: The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.
    Type: Application
    Filed: January 27, 2012
    Publication date: May 17, 2012
    Applicant: NeurAxon, Inc.
    Inventors: Jailall RAMNAUTH, Subhash C. Annedi, Sarah Silverman, Peter Dove, Shawn Maddaford, Suman Rakhit
  • Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity
    Patent number: 8173813
    Abstract: The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: May 8, 2012
    Assignee: NeurAxon, Inc.
    Inventors: Shawn Maddaford, Jailall Ramnauth, Suman Rakhit, Joanne Patman, Subhash C. Annedi, John Andrews, Peter Dove, Sarah Silverman, Paul Renton
  • Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity
    Patent number: 8106043
    Abstract: The present invention features benzothiazines that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms, and that have the formula: The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: January 31, 2012
    Assignee: NeurAxon, Inc.
    Inventors: Jailall Ramnauth, Subhash C. Annedi, Sarah Silverman, Peter Dove, Shawn Maddaford, Suman Rakhit
  • mGluR5 modulators
    Patent number: 7772235
    Abstract: The present invention is directed to compounds of formula I: Wherein R1 to R5, X and Z are further defined in the description. The invention also relates to processes for the preparation of the compounds and to intermediates used in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: August 10, 2010
    Assignee: Astrazeneca AB
    Inventors: Methvin Isaac, Abdelmalik Slassi, Louise Edwards, Peter Dove, Tao Xin, Tomislav Stefanac
  • BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY
    Publication number: 20100009975
    Abstract: The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.
    Type: Application
    Filed: July 6, 2009
    Publication date: January 14, 2010
    Inventors: Jailall Ramnauth, Subhash C. Annedi, Sarah Silverman, Peter Dove, Shawn Maddaford, Suman Rakhit